Grace Therapeutics has announced the initial closure of a financing round, securing almost $15m, to fund the pre-commercial ...

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential ...

Introduction: Urgent external ventricular drain (EVD) placement in aneurysmal subarachnoid hemorrhage (aSAH) is necessary for hydrocephalus treatment. However, it is unclear whether more rapid EVD ...

It was laterally encasing the bilateral internal mammary arteries (IMA) and posteriorly involving the prevascular compartment of the mediastinum. Biopsy revealed a diagnosis of aneurysmal bone cyst.

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Applic ...

Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 ...

By following a strict management protocol for SAH, the hypothesis has been tested that in the modern arena of treatment for aneurysmal SAH the timing of surgery to secure supratentorial aneurysms does ...

Craig-Hallum raised the firm’s price target on Grace Therapeutics (GRCE) to $11 from $8 and keeps a Buy rating on the shares following the ...

Introduction Aneurysmal subarachnoid haemorrhage (aSAH) is a devastating disease associated with high mortality and morbidity. The main threat to patients is delayed cerebral ischaemia (DCI).

Patients who experience a nonaneurysmal subarachnoid hemorrhage differ from patients who suffer an aneurysmal subarachnoid hemorrhage in initial presentation (including neurological examination ...

Introduction: Guidelines for aneurysmal subarachnoid hemorrhage (aSAH) suggest attempting aneurysm securement within 24 hours from arrival; the optimal treatment window within that timeframe is under ...

This reduced thrombogenicity may make it possible to use safely in the acute treatment of aneurysmal subarachnoid haemorrhage (aSAH) on single antiplatelet therapy (SAPT). Objective To evaluate the ...